Gland Pharma Ltd.
- ECONOMY
Gland Pharma Q1 Review – Supply Constraints Play Spoilsport; Margins Remain Resilient: Nirmal Bang
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More » - ECONOMY
Gland Pharma Q1 Review – A Forgettable Quarter; All Eyes On Revenue Recovery: Yes Securities
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More » - ECONOMY
Gland Pharma Q1 Review – India, Rest Of World Hurt Earnings: Motilal Oswal
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More » - ECONOMY
Gland Pharma Q1 Results: Profit Falls 35%, Misses Estimates
Gland Pharma Ltd.’s first-quarter profit declined, missing forecasts. Net profit of the Hyderabad-based generic injectable manufacturer fell 35% year-on-year to…
Read More » - ECONOMY
Q1 FY23 Earnings Preview – Management Commentaries On Demand Critical: Axis Securities
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More » - ECONOMY
Q1 FY23 Earnings Preview – A Glass Half-Full: Motilal Oswal
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More » - ECONOMY
Q3 Earnings Review – Festive Season Brings Limited Cheer; Cost Inflation Impairs Gross Margins: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More »
